The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Get the Name & Ticker Here
Dwight Moxie net worth and biography

Dwight Moxie Biography and Net Worth

Dwight Moxie joined Revance in 2020 as Corporate Secretary to the Board and as Senior Vice President, General Counsel & Corporate Secretary on the Senior Executive Team. Mr. Moxie leads all legal, governance, and compliance initiatives for Revance.

Mr. Moxie brings extensive legal experience in the biopharma and healthcare sectors, advising and supporting companies developing and commercializing novel drugs. Prior to Revance, he served as the Vice President, Deputy General Counsel at Ultragenyx where he oversaw commercial operations, litigation, research & development and regulatory matters. In this position, Mr. Moxie advised on pharmaceutical education and product marketing activities, including DTC advertisements, improved review systems to support product launches and counseled on matters including clinical trials, labeling and more. Prior to Ultragenyx, he served in various legal counsel positions at Allergan and GlaxoSmithKline.

Mr. Moxie holds a J.D. degree from Howard University School of Law and a Bachelor of Arts in Social Science from Florida State University.

What is Dwight Moxie's net worth?

The estimated net worth of Dwight Moxie is at least $1.11 million as of September 14th, 2022. Mr. Moxie owns 31,694 shares of Revance Therapeutics stock worth more than $1,105,170 as of February 6th. This net worth approximation does not reflect any other assets that Mr. Moxie may own. Learn More about Dwight Moxie's net worth.

What is Dwight Moxie's salary?

As the SVP of Revance Therapeutics, Inc., Mr. Moxie earned a total compensation package of $4,519,508.00 in 2020. Mr. Moxie earned a salary of $370,104.00, a bonus of $125,000.00, stock awards of $1,309,383.00, options awards of $2,579,240.00, non-equity compensation of $125,426.00, and other compensation of $10,356.00. Learn More on Dwight Moxie's salary.

How do I contact Dwight Moxie?

The corporate mailing address for Mr. Moxie and other Revance Therapeutics executives is 7555 GATEWAY BLVD., NEWARK CA, 94560. Revance Therapeutics can also be reached via phone at (615) 724-7755 and via email at [email protected] Learn More on Dwight Moxie's contact information.

Has Dwight Moxie been buying or selling shares of Revance Therapeutics?

Dwight Moxie has not been actively trading shares of Revance Therapeutics over the course of the past ninety days. Most recently, Dwight Moxie sold 11,000 shares of the business's stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $27.07, for a transaction totalling $297,770.00. Following the completion of the sale, the senior vice president now directly owns 31,694 shares of the company's stock, valued at $857,956.58. Learn More on Dwight Moxie's trading history.

Who are Revance Therapeutics' active insiders?

Revance Therapeutics' insider roster includes Mark Foley (CEO), Dwight Moxie (SVP), Aubrey Rankin (Insider), Angus Russell (Director), and Tobin Schilke (CFO & Principal Accounting Officer ). Learn More on Revance Therapeutics' active insiders.

Are insiders buying or selling shares of Revance Therapeutics?

In the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 18,902 shares worth more than $540,043.76. The most recent insider tranaction occured on February, 1st when CFO Tobin Schilke sold 3,201 shares worth more than $110,754.60. Insiders at Revance Therapeutics own 5.1% of the company. Learn More about insider trades at Revance Therapeutics.

Information on this page was last updated on 2/1/2023.

Dwight Moxie Insider Trading History at Revance Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/14/2022Sell11,000$27.07$297,770.0031,694View SEC Filing Icon  
9/27/2021Sell1,675$30.00$50,250.00View SEC Filing Icon  
See Full Table

Dwight Moxie Buying and Selling Activity at Revance Therapeutics

This chart shows Dwight Moxie's buying and selling at Revance Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Revance Therapeutics Company Overview

Revance Therapeutics logo
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
Read More

Today's Range

Now: $34.42
Low: $34.12
High: $35.58

50 Day Range

MA: $24.94
Low: $18.32
High: $35.27

2 Week Range

Now: $34.42
Low: $11.27
High: $35.99

Volume

692,491 shs

Average Volume

2,121,966 shs

Market Capitalization

$2.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87